SCHEMBL460287

SCHEMBL460287

CCOC(=O)c1ccc(NC(=O)c2cnc(NC(=O)N3CCC(=Cc4ccccn4)CC3)s2)cc1

nearest known ligand 0.53

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.53
MAPK1 P28482 3/20 0.53
KDM4E B2RXH2 3/20 0.53
MAPT P10636 3/20 0.53
HTT P42858 2/20 0.53
HSD17B10 Q99714 1/20 0.53
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
RAB9A P51151 7/20 0.46
NPC1 O15118 7/20 0.46
SMN1; SMN2 Q16637 7/20 0.46
P2RY12 Q9H244 1/20 0.45
GAA P10253 2/20 0.42
TP53 P04637 2/20 0.41
POLB P06746 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL459750 0.88 OGA (0.41) ALDH1A1MAPK1KDM4EMAPTHTT
SCHEMBL15051480 0.84 OGA (0.44) MEN1KMT2ARAB9ANPC1SMN1; SMN2
SCHEMBL458850 0.83 MAPT (0.50) ALDH1A1MAPK1KDM4EMAPTHTT
SCHEMBL457698 0.80 NAMPT (0.40) ALDH1A1KDM4EMAPT
SCHEMBL458611 0.80 OGA (0.42) ALDH1A1KDM4ERAB9ANPC1SMN1; SMN2
SCHEMBL460463 0.78 OGA (0.45) ALDH1A1MAPK1KDM4EMAPTHTT
SCHEMBL460193 0.77 GRM5 (0.44) KDM4EHSD17B10MEN1KMT2ARAB9A
SCHEMBL457632 0.76 OGA (0.42) ALDH1A1MAPK1KDM4EMAPTHTT
SCHEMBL458505 0.74 CNR2 (0.49)
SCHEMBL15051984 0.73 OGA (0.41) ALDH1A1KDM4EP2RY12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2615084-B1 PROSTAGLANDIN D SYNTHASE INHIBITORY PIPERIDINE COMPOUNDS TAIHO PHARMACEUTICAL CO LTD (JP) 2016-01-06 EP disclosed
US-9181183-B2 Prostaglandin D synthase inhibitory piperidine compounds TAIHO PHARMACEUTICAL CO., LTD. (JP) 2015-11-10 US disclosed
CN-103080086-B Prostaglandin D synthase inhibitory piperidine compounds TAIHO PHARMACEUTICAL CO LTD 2014-11-05 CN disclosed
EP-2615084-A1 PROSTAGLANDIN D SYNTHASE INHIBITORY PIPERIDINE COMPOUNDS Taiho Pharmaceutical Co., Ltd. (JP) 2013-07-17 EP disclosed
US-20130165438-A1 PROSTAGLANDIN D SYNTHASE INHIBITORY PIPERIDINE COMPOUNDS TAIHO PHARMACEUTICAL CO., LTD. (JP) 2013-06-27 US disclosed
CN-103080086-A Prostaglandin D synthase inhibitory piperidine compounds TAIHO PHARMACEUTICAL CO LTD 2013-05-01 CN disclosed
WO-2012033069-A1 PROSTAGLANDIN D SYNTHASE INHIBITORY PIPERIDINE COMPOUNDS 大鵬薬品工業株式会社 (JP) 2012-03-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130165438-A1 PROSTAGLANDIN D SYNTHASE INHIBITORY PIPERIDINE COMPOUNDS PTGIS, PTGS1, PTGDR ALDH1A1 157/4885MAPK1 2086/4885KDM4E 2721/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.